Saturday 17 October 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
16.65
0.60
−3.48%
Follow NEO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.47 | 1.28 | 2.07 | 1.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
94.76 | (117.78) | 1,121.72 | 111.59 | |
P/B ratio |
2.41 | 1.16 | 1.80 | 1.18 | |
Price to Tangible BV |
0.00 | 37.05 | 58.64 | 50.11 | |
EV/Sales |
3.03 | 1.82 | 2.60 | 1.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
105.45 | 60.47 | 361.35 | 100.08 | |
EV/FCF |
(439.62) | (448.59) | (95.87) | (80.35) | |
Quick Ratio |
3.03 | 3.71 | 3.61 | 3.26 | |
Current Ratio |
3.60 | 4.42 | 4.26 | 3.91 | |
Net Debt/EBITDA |
32.27 | (107.27) | 54.18 | (17.39) | |
Debt/Assets |
27.97% | 25.42% | 25.14% | 24.84% | |
Debt/Equity |
0.48 | 0.41 | 0.41 | 0.41 | |
Asset Turnover |
0.56 | 0.51 | 0.49 | 0.47 | |
Operating CF/Net income |
8.92 | 0.48 | (0.14) | (0.33) | |
Capex/Depreciation |
(0.48) | (0.30) | (0.35) | (0.49) | |
Interest Coverage |
(12.51) | (30.50) | (22.39) | (44.80) | |
Research and Development Expense of Revenue |
5.34% | 5.11% | 4.83% | 4.63% | |
Selling, General and Administrative Expense of Revenue |
45.07% | 47.98% | 45.72% | 48.82% | |
Intangible Assets out of Total Assets |
0.59 | 0.60 | 0.60 | 0.60 | |
Share Based Compensation of Revenue |
4.07% | 5.16% | 4.23% | 5.49% | |
Graham Net Nets |
(0.10) | (0.15) | (0.10) | (0.16) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.74%) | (10.38%) | (7.14%) | (11.40%) | |
Free Cash Flow Yield |
(0.28%) | (0.32%) | (1.31%) | (1.72%) | |
Revenue per Share |
1.56 | 1.45 | 1.48 | 1.46 | |
Operating CF per Share |
0.15 | (0.06) | 0.01 | 0.07 | |
Capex per Share |
(0.06) | (0.04) | (0.05) | (0.06) | |
Free Cash Flow per Share |
0.09 | (0.10) | (0.03) | 0.00 | |
Cash per Share |
1.12 | 1.13 | 1.25 | 1.28 | |
Shareholders Equity per Share |
6.06 | 6.42 | 6.53 | 6.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.06 | 6.42 | 6.53 | 6.53 | |
Free Cash Flow |
11.74 | (13.14) | (4.46) | 0.57 | |
Working Capital |
275.60 | 289.09 | 287.99 | 284.60 | |
Capital Expenditures |
(8.22) | (5.00) | (5.80) | (8.31) | |
Net Current Asset Value |
(185.03) | (144.09) | (146.98) | (154.02) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
164.27 | 159.32 | 154.89 | 153.36 | |
Average Payables |
24.22 | 21.05 | 22.35 | 19.56 | |
Average Inventory |
30.65 | 29.80 | 27.66 | 26.46 | |
Average Assets |
1,373.10 | 1,473.98 | 1,498.93 | 1,507.95 | |
Average Common Equity |
819.89 | 858.51 | 869.45 | 873.25 |
Columns are period end dates